Status:
COMPLETED
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
Lead Sponsor:
Gannex Pharma Co., Ltd.
Collaborating Sponsors:
Hunan Provincial People's Hospital
Conditions:
Overweight and Obesity
NAFLD
Eligibility:
All Genders
18-59 years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have ele...
Eligibility Criteria
Inclusion
- Key
- 23kg/m2 ≤ BMI \<40kg/m2.
- Key
Exclusion
- A history of thyroid disease.
- A positive HBsAg, HCV Ab and/or HIV Ab.
Key Trial Info
Start Date :
December 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 7 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04686994
Start Date
December 22 2020
End Date
February 7 2021
Last Update
September 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hunan provincial people's hospital
Changsha, Hunan, China